1. Home
  2. KXIN vs BCDA Comparison

KXIN vs BCDA Comparison

Compare KXIN & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KXIN
  • BCDA
  • Stock Information
  • Founded
  • KXIN 2015
  • BCDA N/A
  • Country
  • KXIN China
  • BCDA United States
  • Employees
  • KXIN N/A
  • BCDA N/A
  • Industry
  • KXIN Retail-Auto Dealers and Gas Stations
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • KXIN Consumer Discretionary
  • BCDA Health Care
  • Exchange
  • KXIN Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • KXIN 10.4M
  • BCDA 10.1M
  • IPO Year
  • KXIN N/A
  • BCDA N/A
  • Fundamental
  • Price
  • KXIN $0.78
  • BCDA $2.13
  • Analyst Decision
  • KXIN
  • BCDA Strong Buy
  • Analyst Count
  • KXIN 0
  • BCDA 1
  • Target Price
  • KXIN N/A
  • BCDA $25.00
  • AVG Volume (30 Days)
  • KXIN 144.3K
  • BCDA 83.8K
  • Earning Date
  • KXIN 01-01-0001
  • BCDA 08-12-2025
  • Dividend Yield
  • KXIN N/A
  • BCDA N/A
  • EPS Growth
  • KXIN N/A
  • BCDA N/A
  • EPS
  • KXIN N/A
  • BCDA N/A
  • Revenue
  • KXIN N/A
  • BCDA $3,000.00
  • Revenue This Year
  • KXIN N/A
  • BCDA N/A
  • Revenue Next Year
  • KXIN N/A
  • BCDA N/A
  • P/E Ratio
  • KXIN N/A
  • BCDA N/A
  • Revenue Growth
  • KXIN N/A
  • BCDA N/A
  • 52 Week Low
  • KXIN $0.64
  • BCDA $1.63
  • 52 Week High
  • KXIN $29.54
  • BCDA $4.66
  • Technical
  • Relative Strength Index (RSI)
  • KXIN 36.20
  • BCDA 43.00
  • Support Level
  • KXIN $0.81
  • BCDA $2.22
  • Resistance Level
  • KXIN $0.85
  • BCDA $2.42
  • Average True Range (ATR)
  • KXIN 0.06
  • BCDA 0.12
  • MACD
  • KXIN -0.01
  • BCDA -0.02
  • Stochastic Oscillator
  • KXIN 27.21
  • BCDA 20.53

About KXIN Kaixin Auto Holdings

Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: